BioMed Research International

Copyright © 2014 Mario Quarantelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. H. Elkis, “Treatment-resistant schizophrenia,” Psychiatric Clinics of North America, vol. 30, no. 3, pp. 511–533, 2007. View at Publisher · View at Google Scholar · View at Scopus
2. R. R. Conley and D. L. Kelly, “Management of treatment resistance in schizophrenia,” Biological Psychiatry, vol. 50, no. 11, pp. 898–911, 2001. View at Publisher · View at Google Scholar · View at Scopus
3. J. Lindenmayer, “Treatment refractory schizophrenia,” Psychiatric Quarterly, vol. 71, no. 4, pp. 373–384, 2000. View at Publisher · View at Google Scholar · View at Scopus
4. S. M. Essock, W. A. Hargreaves, N. H. Covell, and J. Goethe, “Clozapine's effectiveness for patients in state hospitals: results from a randomized trial,” Psychopharmacology Bulletin, vol. 32, no. 4, pp. 683–697, 1996. View at Google Scholar
5. H. D. Brenner, S. J. Dencker, M. J. Goldstein et al., “Defining treatment refractoriness in schizophrenia,” Schizophrenia Bulletin, vol. 16, no. 4, pp. 551–561, 1990. View at Publisher · View at Google Scholar · View at Scopus
6. R. R. Conley and R. W. Buchanan, “Evaluation of treatment-resistant schizophrenia,” Schizophrenia Bulletin, vol. 23, no. 4, pp. 663–674, 1997. View at Publisher · View at Google Scholar · View at Scopus
7. J. L. Kennedy, C. A. Altar, D. L. Taylor, I. Degtiar, and J. C. Hornberger, “The social and economic burden of treatment-resistant schizophrenia: a systematic literature review,” International Clinical Psychopharmacology, vol. 29, no. 2, pp. 63–76, 2014. View at Publisher · View at Google Scholar
8. A. de Bartolomeis, R. Balletta, S. Giordano, E. F. Buonaguro, G. Latte, and F. Iasevoli, “Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses,” Psychiatry Research, vol. 210, no. 2, pp. 387–395, 2013. View at Publisher · View at Google Scholar · View at Scopus
9. J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, “Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine,” Archives of General Psychiatry, vol. 45, no. 9, pp. 789–796, 1988. View at Publisher · View at Google Scholar · View at Scopus
10. J. Lieberman, D. Jody, S. Geisler et al., “Time course and biologic correlates of treatment response in first-episode schizophrenia,” Archives of General Psychiatry, vol. 50, no. 5, pp. 369–376, 1993. View at Publisher · View at Google Scholar · View at Scopus
11. H. Y. Meltzer, J. Rabinowitz, M. A. Lee et al., “Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance,” The American Journal of Psychiatry, vol. 154, no. 4, pp. 475–482, 1997. View at Google Scholar · View at Scopus
12. E. C. Johnstone, D. G. C. Owens, G. M. Bydder, N. Colter, T. J. Crow, and C. D. Frith, “The spectrum of structural brain changes in schizophrenia: age of onset as a predictor of cognitive and clinical impairments and their cerebral correlates,” Psychological Medicine, vol. 19, no. 1, pp. 91–103, 1989. View at Publisher · View at Google Scholar · View at Scopus
13. T. Kolakowska, A. O. Williams, M. Ardern et al., “Schizophrenia with good and poor outcome. I: early clinical features, response to neuroleptics and signs of organic dysfunction,” British Journal of Psychiatry, vol. 146, pp. 229–239, 1985. View at Publisher · View at Google Scholar · View at Scopus
14. L. Friedman, L. Knutson, M. Shurell, and H. Y. Meltzer, “Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia,” Biological Psychiatry, vol. 29, no. 9, pp. 865–877, 1991. View at Publisher · View at Google Scholar · View at Scopus
15. W. G. Honer, G. N. Smith, J. S. Lapointe, G. W. MacEwan, L. Kopala, and S. Altman, “Regional cortical anatomy and clozapine response in refractory schizophrenia,” Neuropsychopharmacology, vol. 13, no. 1, pp. 85–87, 1995. View at Publisher · View at Google Scholar · View at Scopus
16. S. M. Lawrie, G. T. Ingle, C. G. Santosh et al., “Magnetic resonance imaging and single photon emission tomography in treatment-responsive and treatment-resistant schizophrenia,” British Journal of Psychiatry, vol. 167, pp. 202–210, 1995. View at Publisher · View at Google Scholar · View at Scopus
17. S. M. Lawrie, S. S. Abukmeil, A. Chiswick, V. Egan, C. G. Santosh, and J. J. K. Best, “Qualitative cerebral morphology in schizophrenia: A magnetic resonance imaging study and systematic literature review,” Schizophrenia Research, vol. 25, no. 2, pp. 155–166, 1997. View at Publisher · View at Google Scholar · View at Scopus
18. P. E. Konicki, K. Y. Kwon, V. Steele et al., “Prefrontal cortical sulcal widening associated with poor treatment response to clozapine,” Schizophrenia Research, vol. 48, no. 2-3, pp. 173–176, 2001. View at Publisher · View at Google Scholar · View at Scopus
19. H. A. Savas, B. Unal, H. Erbagci et al., “Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study,” Neuropsychobiology, vol. 46, no. 2, pp. 61–66, 2002. View at Publisher · View at Google Scholar · View at Scopus
20. V. Molina, S. Reig, J. Sanz et al., “Differential clinical, structural and P300 parameters in schizophrenia patients resistant to conventional neuroleptics,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 32, no. 1, pp. 257–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
21. C. Arango, A. Breier, R. McMahon, W. T. Carpenter Jr., and R. W. Buchanan, “The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes,” American Journal of Psychiatry, vol. 160, no. 8, pp. 1421–1427, 2003. View at Publisher · View at Google Scholar · View at Scopus
22. R. B. Zipursky, J. Zhang-Wong, E. K. Lambe, G. Bean, and M. Beiser, “MRI correlates of treatment response in first episode psychosis,” Schizophrenia Research, vol. 30, no. 1, pp. 81–90, 1998. View at Publisher · View at Google Scholar · View at Scopus
23. D. M. Gardner, A. L. Murphy, H. O'Donnell, F. Centorrino, and R. J. Baldessarini, “International consensus study of antipsychotic dosing,” The American Journal of Psychiatry, vol. 167, no. 6, pp. 686–693, 2010. View at Publisher · View at Google Scholar · View at Scopus
24. N. Tzourio-Mazoyer, B. Landeau, D. Papathanassiou et al., “Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain,” NeuroImage, vol. 15, no. 1, pp. 273–289, 2002. View at Publisher · View at Google Scholar · View at Scopus
25. R. Roncone, J. Ventura, M. Impallomeni et al., “Reliability of an Italian standardized and expanded Brief Psychiatric Rating Scale (BPRS 4.0) in raters with high vs. low clinical experience,” Acta Psychiatrica Scandinavica, vol. 100, no. 3, pp. 229–236, 1999. View at Publisher · View at Google Scholar · View at Scopus
26. O. Kalla, J. Aaltonen, J. Wahl-ström, V. Lehtinen, I. García Cabeza, and M. González De Chávez, “Duration of untreated psychosis and its correlates first-episode psychosis in Finland and Spain,” Acta Psychiatrica Scandinavica, vol. 106, no. 4, pp. 265–275, 2002. View at Publisher · View at Google Scholar · View at Scopus
27. NICE, Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care, National Institute for Health and Clinical Excellence, London, UK, 2002.
28. NICE, Schizophrenia; Full National Clinical Guidelines on Core Interventions in Primary and Secondary Care, National Institute for Health and Clinical Excellence, London, UK, 2003.
29. D. I. Velligan, Y. F. Lam, D. C. Glahn et al., “Defining and assessing adherence to oral antipsychotics: a review of the literature,” Schizophrenia Bulletin, vol. 32, no. 4, pp. 724–742, 2006. View at Publisher · View at Google Scholar · View at Scopus
30. J. Ventura, K. H. Nuechterlein, K. L. Subotnik, D. Gutkind, and E. A. Gilbert, “Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale,” Psychiatry Research, vol. 97, no. 2-3, pp. 129–135, 2000. View at Publisher · View at Google Scholar · View at Scopus
31. M. G. Harris, L. P. Henry, S. M. Harrigan et al., “The relationship between duration of untreated psychosis and outcome: an eight-year prospective study,” Schizophrenia Research, vol. 79, no. 1, pp. 85–93, 2005. View at Publisher · View at Google Scholar · View at Scopus
32. J. P. Lyne, A. Kinsella, and B. O'Donoghue, “Can we combine symptom scales for collaborative research projects?” Journal of Psychiatric Research, vol. 46, no. 2, pp. 233–238, 2012. View at Publisher · View at Google Scholar · View at Scopus
33. J. Welham, T. Stedman, and A. Clair, “Choosing negative symptom instruments: issues of representation and redundancy,” Psychiatry Research, vol. 87, no. 1, pp. 47–56, 1999. View at Publisher · View at Google Scholar · View at Scopus
34. S. L. Eckert, P. M. Diamond, A. L. Miller, D. I. Velligan, L. G. Funderburg, and J. E. True, “A comparison of instrument sensitivity to negative symptom change,” Psychiatry Research, vol. 63, no. 1, pp. 67–75, 1996. View at Publisher · View at Google Scholar · View at Scopus
35. J. Ashburner and K. J. Friston, “Unified segmentation,” NeuroImage, vol. 26, no. 3, pp. 839–851, 2005. View at Publisher · View at Google Scholar · View at Scopus
36. J. Ashburner and K. J. Friston, “Nonlinear spatial normalization using basis functions,” Human Brain Mapping, vol. 7, no. 4, pp. 254–266, 1999. View at Google Scholar
37. C. D. Good, I. S. Johnsrude, J. Ashburner, R. N. A. Henson, K. J. Friston, and R. S. J. Frackowiak, “A voxel-based morphometric study of ageing in 465 normal adult human brains,” NeuroImage, vol. 14, no. 1, part 1, pp. 21–36, 2001. View at Publisher · View at Google Scholar · View at Scopus
38. J. Ashburner and K. J. Friston, “Voxel-based morphometry—the methods,” NeuroImage, vol. 11, no. 6, part 1, pp. 805–821, 2000. View at Publisher · View at Google Scholar · View at Scopus
39. E. T. Bullmore, J. Suckling, S. Overmeyer, S. Rabe-Hesketh, E. Taylor, and M. J. Brammer, “Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain,” IEEE Transactions on Medical Imaging, vol. 18, no. 1, pp. 32–42, 1999. View at Publisher · View at Google Scholar · View at Scopus
40. J. Suckling and E. Bullmore, “Permutation tests for factorially designed neuroimaging experiments,” Human Brain Mapping, vol. 22, no. 3, pp. 193–205, 2004. View at Publisher · View at Google Scholar · View at Scopus
41. C. Pantelis, D. Velakoulis, P. D. McGorry et al., “Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison,” The Lancet, vol. 361, no. 9354, pp. 281–288, 2003. View at Publisher · View at Google Scholar · View at Scopus
42. B. Turetsky, P. E. Cowell, R. C. Gur, R. I. Grossman, D. L. Shtasel, and R. E. Gur, “Frontal and temporal lobe brain volumes in schizophrenia: relationship to symptoms and clinical subtype,” Archives of General Psychiatry, vol. 52, no. 12, pp. 1061–1070, 1995. View at Publisher · View at Google Scholar · View at Scopus
43. G. Okugawa, G. C. Sedvall, and I. Agartz, “Reduced grey and white matter volumes in the temporal lobe of male patients with chronic schizophrenia,” European Archives of Psychiatry and Clinical Neuroscience, vol. 252, no. 3, pp. 120–123, 2002. View at Publisher · View at Google Scholar · View at Scopus
44. D. C. Glahn, A. R. Laird, I. Ellison-Wright et al., “Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis,” Biological Psychiatry, vol. 64, no. 9, pp. 774–781, 2008. View at Publisher · View at Google Scholar · View at Scopus
45. V. Molina, C. Martín, A. Ballesteros, A. G. S. De Herrera, and J. A. Hernández-Tamames, “Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics,” European Archives of Psychiatry and Clinical Neuroscience, vol. 261, no. 6, pp. 407–416, 2011. View at Publisher · View at Google Scholar · View at Scopus
46. V. Molina, S. Reig, J. Sanz et al., “Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia,” Schizophrenia Research, vol. 80, no. 1, pp. 61–71, 2005. View at Publisher · View at Google Scholar · View at Scopus
47. E. Stip, A. Mancini-Marïe, G. Letourneau et al., “Increased grey matter densities in schizophrenia patients with negative symptoms after treatment with quetiapine: a voxel-based morphometry study,” International Clinical Psychopharmacology, vol. 24, no. 1, pp. 34–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
48. L. Tomelleri, J. Jogia, C. Perlini et al., “Brain structural changes associated with chronicity and antipsychotic treatment in schizophrenia,” European Neuropsychopharmacology, vol. 19, no. 12, pp. 835–840, 2009. View at Publisher · View at Google Scholar · View at Scopus
49. N. E. M. Van Haren, H. E. Hulshoff Pol, H. G. Schnack et al., “Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study,” Neuropsychopharmacology, vol. 32, no. 10, pp. 2057–2066, 2007. View at Publisher · View at Google Scholar · View at Scopus
50. V. Molina, J. A. Hernández, J. Sanz et al., “Subcortical and cortical gray matter differences between Kraepelinian and non-Kraepelinian schizophrenia patients identified using voxel-based morphometry,” Psychiatry Research, vol. 184, no. 1, pp. 16–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
51. J. L. Knoll IV, D. L. Garver, J. E. Ramberg, S. J. Kingsbury, D. Croissant, and B. McDermott, “Heterogeneity of the psychoses: is there a neurodegenerative psychosis?” Schizophrenia Bulletin, vol. 24, no. 3, pp. 365–379, 1998. View at Publisher · View at Google Scholar · View at Scopus
52. I. Nenadic, H. Sauer, and C. Gaser, “Distinct pattern of brain structural deficits in subsyndromes of schizophrenia delineated by psychopathology,” NeuroImage, vol. 49, no. 2, pp. 1153–1160, 2010. View at Publisher · View at Google Scholar · View at Scopus
53. T. E. Bakken, C. S. Bloss, J. C. Roddey et al., “Association of genetic variants on 15q12 with cortical thickness and cognition in schizophrenia,” Archives of General Psychiatry, vol. 68, no. 8, pp. 781–790, 2011. View at Publisher · View at Google Scholar
54. V. Oertel-Knöchel, C. Knöchel, A. Rotarska-Jagiela et al., “Association between psychotic symptoms and cortical thickness reduction across the schizophrenia spectrum,” Cerebral Cortex, vol. 23, no. 1, pp. 61–70, 2013. View at Publisher · View at Google Scholar · View at Scopus
55. M. Leung, C. Cheung, K. Yu et al., “Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment: anatomical likelihood estimation meta-analyses with sample size weighting,” Schizophrenia Bulletin, vol. 37, no. 1, pp. 199–211, 2011. View at Publisher · View at Google Scholar · View at Scopus
56. R. Smieskova, P. Fusar-Poli, P. Allen et al., “The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?—a systematic review,” Current Pharmaceutical Design, vol. 15, no. 22, pp. 2535–2549, 2009. View at Publisher · View at Google Scholar · View at Scopus
57. S. Navari and P. Dazzan, “Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings,” Psychological Medicine, vol. 39, no. 11, pp. 1763–1777, 2009. View at Publisher · View at Google Scholar · View at Scopus
58. N. E. M. Van Haren, H. G. Schnack, W. Cahn et al., “Changes in cortical thickness during the course of illness in schizophrenia,” Archives of General Psychiatry, vol. 68, no. 9, pp. 871–880, 2011. View at Publisher · View at Google Scholar · View at Scopus
59. B. Ho, N. C. Andreasen, S. Ziebell, R. Pierson, and V. Magnotta, “Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia,” Archives of General Psychiatry, vol. 68, no. 2, pp. 128–137, 2011. View at Publisher · View at Google Scholar · View at Scopus
60. N. C. Andreasen, P. Nopoulos, V. Magnotta, R. Pierson, S. Ziebell, and B. Ho, “Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia,” Biological Psychiatry, vol. 70, no. 7, pp. 672–679, 2011. View at Publisher · View at Google Scholar · View at Scopus
61. W. Poser, S. Poser, D. Roscher, and A. Argyrakis, “Do benzodiazepines cause cerebral atrophy?” The Lancet, vol. 1, no. 8326, p. 715, 1983. View at Publisher · View at Google Scholar · View at Scopus
62. R. S. N. Liu, L. Lemieux, G. S. Bell et al., “Cerebral damage in epilepsy: a population-based longitudinal quantitative MRI study,” Epilepsia, vol. 46, no. 9, pp. 1482–1494, 2005. View at Publisher · View at Google Scholar · View at Scopus
63. D. G. Robinson, M. G. Woerner, J. M. J. Alvir et al., “Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder,” The American Journal of Psychiatry, vol. 156, no. 4, pp. 544–549, 1999. View at Google Scholar · View at Scopus
64. J. Peuskens, “The evolving definition of treatment resistance,” Journal of Clinical Psychiatry, vol. 60, no. 12, pp. 4–8, 1999. View at Google Scholar · View at Scopus